This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT07881432 |
|---|---|
| Status | Not yet recruiting |
| Phase | Phase 3 |
| Sponsor | Eli Lilly and Company |
| Enrollment | 2,115 participants |
| Design | Interventional, Randomized, Parallel, Masking: Double |
| Conditions | Obesity |
| Interventions | eloralintide and tirzepatide; Eloralintide; Tirzepatide; Placebo |
| Start | Dec 2026 |
| Primary completion | Oct 2029 |
| Study completion | Nov 2029 |
| Results posted | Not yet |
| Registry last updated | Oct 19, 2026 |
Compounds on this site that cite this trial
What the registry says the trial is about
The purpose of this study is to investigate the efficacy and safety of eloralintide and tirzepatide coformulation (EloraTZP) compared with tirzepatide, eloralintide and placebo for body weight reduction in participants with obesity.
Participation in the study will last about 2 years.
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Percent Change from Baseline in Body Weight | Baseline, Week 100 |
20 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 30, 2026. See the trial changes feed for what has changed recently.
More trials of Eloralintide
- Eloralintide and Tirzepatide: Phase 3 Trial (NCT07881458)
- Eloralintide and Tirzepatide: Phase 2 Trial (NCT06603571)
- Eloralintide: Phase 2 Trial in Obesity (NCT06230523)
- Eloralintide: Phase 1 Trial in Obesity (NCT07808060)
- Eloralintide: Phase 1 Trial in Obesity (NCT05295940)
Research area: Metabolic and incretin. Every registered trial we follow is in the clinical trial tracker, and the labels used on this page are explained in our evidence standards.
